Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Weight gain and antipsychotics: a drug safety review
Richard Musil, Michael Obermeier, Paul Russ, et al.
Expert Opinion on Drug Safety (2014) Vol. 14, Iss. 1, pp. 73-96
Closed Access | Times Cited: 182

Showing 1-25 of 182 citing articles:

Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline
Dennis M. Styne, Silva Arslanian, Ellen L. Connor, et al.
The Journal of Clinical Endocrinology & Metabolism (2017) Vol. 102, Iss. 3, pp. 709-757
Open Access | Times Cited: 1091
Neuronal Regulation of Energy Homeostasis: Beyond the Hypothalamus and Feeding
Michael Waterson, Tamas L. Horváth
Cell Metabolism (2015) Vol. 22, Iss. 6, pp. 962-970
Open Access | Times Cited: 376
Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis
Varuni De Silva, Chathurie Suraweera, S. S. Ratnatunga, et al.
BMC Psychiatry (2016) Vol. 16, Iss. 1
Open Access | Times Cited: 192
Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis
Barbara B. Barton, Felix Segger, Kai Fischer, et al.
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 3, pp. 295-314
Closed Access | Times Cited: 163
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials
Hui Wu, Spyridon Siafis, Tasnim Hamza, et al.
Schizophrenia Bulletin (2022) Vol. 48, Iss. 3, pp. 643-654
Open Access | Times Cited: 73
An update of safety of clinically used atypical antipsychotics
Laura Orsolini, Carmine Tomasetti, A. Valchera, et al.
Expert Opinion on Drug Safety (2016) Vol. 15, Iss. 10, pp. 1329-1347
Closed Access | Times Cited: 127
Using Causal Diagrams to Improve the Design and Interpretation of Medical Research
Mahyar Etminan, Gary S. Collins, Mohammad Alì Mansournia
CHEST Journal (2020) Vol. 158, Iss. 1, pp. S21-S28
Open Access | Times Cited: 100
The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Mark R. Libowitz, Erika L. Nurmi
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 61
Clozapine’s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia
Andrea de Bartolomeis, Licia Vellucci, Annarita Barone, et al.
Pharmacology & Therapeutics (2022) Vol. 236, pp. 108236-108236
Open Access | Times Cited: 49
Obesity as pleiotropic risk state for metabolic and mental health throughout life
Michael Leutner, Elma Dervić, Luise Bellach, et al.
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 38
Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations
Nicolette Stogios, Bailey Humber, Sri Mahavir Agarwal, et al.
Current Psychiatry Reports (2023) Vol. 25, Iss. 11, pp. 707-721
Closed Access | Times Cited: 34
The Health Consequences of Obesity in Young Adulthood
Hoi Lun Cheng, Sharon Medlow, Katharine Steinbeck
Current Obesity Reports (2016) Vol. 5, Iss. 1, pp. 30-37
Closed Access | Times Cited: 76
Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials
Renrong Wu, Fengyu Zhang, K-M Gao, et al.
Molecular Psychiatry (2016) Vol. 21, Iss. 11, pp. 1537-1544
Open Access | Times Cited: 67
New discoveries for an old drug: a review of recent olanzapine research
Amir Mohammad Meftah, Elizabeth Deckler, Leslie Citrome, et al.
Postgraduate Medicine (2019) Vol. 132, Iss. 1, pp. 80-90
Closed Access | Times Cited: 58
Association between antipsychotic medication and clinically relevant weight change: meta-analysis
Bea Campforts, Marjan Drukker, Joost Crins, et al.
BJPsych Open (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 19
Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials
Marco Solmi, Nicola Veronese, Leonardo Zaninotto, et al.
CNS Spectrums (2016) Vol. 21, Iss. 5, pp. 403-418
Closed Access | Times Cited: 60
Prioritizing Environmental Chemicals for Obesity and Diabetes Outcomes Research: A Screening Approach Using ToxCast™ High-Throughput Data
Scott S. Auerbach, Dayne L. Filer, David M. Reif, et al.
Environmental Health Perspectives (2016) Vol. 124, Iss. 8, pp. 1141-1154
Open Access | Times Cited: 59
Practical Use of Pharmacotherapy for Obesity
Leon I. Igel, Rekha B. Kumar, Katherine H. Saunders, et al.
Gastroenterology (2017) Vol. 152, Iss. 7, pp. 1765-1779
Closed Access | Times Cited: 54
Analysis of Gut Microbiota and Their Metabolic Potential in Patients with Schizophrenia Treated with Olanzapine: Results from a Six-Week Observational Prospective Cohort Study
Justyna Pełka-Wysiecka, Mariusz Kaczmarczyk, Agata Bąba-Kubiś, et al.
Journal of Clinical Medicine (2019) Vol. 8, Iss. 10, pp. 1605-1605
Open Access | Times Cited: 53
Cardiovascular safety of antipsychotics: a clinical overview
Christoffer Polcwiartek, Kristian Kragholm, Ole Schjerning, et al.
Expert Opinion on Drug Safety (2016) Vol. 15, Iss. 5, pp. 679-688
Closed Access | Times Cited: 47
Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis
Maarten Bak, Marjan Drukker, Shauna Cortenraad, et al.
PLoS ONE (2021) Vol. 16, Iss. 2, pp. e0244944-e0244944
Open Access | Times Cited: 40
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
Michele Fusaroli, Emanuel Raschi, Valentina Giunchi, et al.
The International Journal of Neuropsychopharmacology (2022) Vol. 25, Iss. 9, pp. 727-736
Open Access | Times Cited: 27
Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review
Qijing Bo, Zhimin Wang, Xianbin Li, et al.
Psychiatry Research (2016) Vol. 237, pp. 257-263
Closed Access | Times Cited: 42
Genetic evidence for a role of the SREBP transcription system and lipid biosynthesis in schizophrenia and antipsychotic treatment
Vidar M. Steen, Silje Skrede, Tatiana Polushina, et al.
European Neuropsychopharmacology (2016) Vol. 27, Iss. 6, pp. 589-598
Closed Access | Times Cited: 42
Obesity in Chinese patients with chronic schizophrenia: Prevalence, clinical correlates and relationship with cognitive deficits
Yang Tian, Dianying Liu, Dongmei Wang, et al.
Schizophrenia Research (2019) Vol. 215, pp. 270-276
Closed Access | Times Cited: 37
Page 1 - Next Page

Scroll to top